Important: This article is for educational purposes only and is not medical advice. Scleroderma is a serious autoimmune connective-tissue disease that should be managed by a board-certified rheumatologist, ideally one with experience in systemic sclerosis. CBD is not approved by the FDA to treat scleroderma. Never replace prescribed medication with a supplement.
Scleroderma — particularly its systemic form, systemic sclerosis — is an autoimmune disease that affects the skin, blood vessels, and in many patients internal organs. Because it involves both immune dysregulation and fibrosis, some patients have asked whether CBD, which has been studied in inflammation and immune-signaling research, might play any role. This page reviews what published research actually examines and is careful not to overstate it.
The short version
- CBD is not a treatment for scleroderma. No CBD product, consumer or pharmaceutical, has been approved by the FDA for scleroderma or systemic sclerosis.
- Published research on CBD specifically in scleroderma is very limited. Most of what exists is preclinical (cell or animal models) and does not establish clinical effects in patients.
- Standard care for systemic sclerosis is highly individualized and includes immunosuppressive therapies, vascular medications (for example for Raynaud’s-related symptoms), and organ-specific care for lung, kidney, gastrointestinal, and cardiac involvement when present.
What scleroderma is, briefly
Scleroderma is a group of autoimmune conditions in which the immune system produces excess collagen, leading to thickening and hardening of tissues. The two broad categories are:
- Localized scleroderma (morphea, linear scleroderma) — primarily affects the skin and subcutaneous tissue.
- Systemic sclerosis — can involve internal organs in addition to the skin. Subcategories include limited cutaneous and diffuse cutaneous forms.
Care is led by a rheumatologist and often involves a multidisciplinary team — pulmonology, cardiology, gastroenterology, and dermatology can each be relevant depending on which organs are affected.
What CBD-and-scleroderma research has actually examined
The published evidence is limited, and being honest about that matters more than overselling.
Preclinical fibrosis research
There is broader cannabinoid research on fibrosis pathways — the biology of excessive scar-tissue formation. Some animal-model and cell-culture studies have examined how cannabinoid signaling intersects with fibroblast activity and TGF-β pathways. This is hypothesis-generating laboratory science. It is not the same as showing that consumer CBD products affect fibrosis in human scleroderma patients.
Immune-modulation research
Cannabinoid receptors are expressed on immune cells, and a body of preclinical work has examined how cannabinoid signaling affects immune cell behavior. Again, this is foundational science, not clinical evidence in scleroderma.
Clinical research specific to systemic sclerosis
Direct clinical research on CBD in scleroderma patients is sparse. There is no large, well-designed, placebo-controlled trial that supports a specific clinical use of CBD in this population.
Drug-interaction considerations specific to scleroderma care
Scleroderma regimens often include immunosuppressive medications (mycophenolate, methotrexate, cyclophosphamide, tocilizumab, rituximab), proton-pump inhibitors for reflux, vasodilators for Raynaud’s, and others. CBD is metabolized through liver enzymes that also process some of these medications. The clinically relevant point is simple: any patient on a scleroderma regimen should review supplement use, including CBD, with their rheumatology team.
What the FDA has said
The FDA has not approved any CBD product for scleroderma. The agency has issued warning letters to companies that have marketed CBD as a treatment for autoimmune or fibrotic diseases. Marketing a product as treating, curing, or preventing such conditions makes it an unapproved new drug under federal law.
Talking to your rheumatologist
If you live with scleroderma and are curious whether CBD might fit into a wellness routine alongside your existing care, an honest conversation with the treating clinician is the right path. Useful questions:
- Are any of my current medications metabolized through pathways CBD also affects?
- Is there any reason I should not use a consumer CBD product?
- If I do try a CBD product, what should I report back about, and is there bloodwork I should monitor?
What we offer at New Phase Blends
We make third-party-tested CBD products designed for general wellness use. They are not formulated, tested, or marketed as treatments for scleroderma or any autoimmune condition. If you have a scleroderma diagnosis, please continue to follow the plan your treating rheumatologist has built for you.
Frequently asked questions
Can CBD treat scleroderma? No. CBD is not approved for scleroderma, and direct clinical research in scleroderma patients is very limited.
Has CBD been FDA-approved for any autoimmune condition? No.
Could CBD interact with my scleroderma medications? It could. CBD shares liver-enzyme pathways with several medications used in scleroderma care. Discuss any supplement use with your rheumatology team.
Where can I learn more about how CBD interacts with the body? Our endocannabinoid system overview walks through the underlying biology in plain language.
Disclaimer: The statements made on this page have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease, including scleroderma or any autoimmune condition. The information here is for educational purposes only and is not a substitute for advice from a licensed medical professional. Always consult your treating rheumatologist before adding any supplement to a scleroderma care plan.
